Home
Search
SurgiMabSurgiMab
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
8th annual meeting of the European Society for Molecular Imaging – ESMI
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
EnglishEnglishFrançaisFrançais

8th annual meeting of the European Society for Molecular Imaging – ESMI

SurgiMab > News & Events > News > 8th annual meeting of the European Society for Molecular Imaging – ESMI
18 May 2013 Administrateur SurgiMabLeave a comment0

On the occasion of the 8th annual meeting of the European Society for Molecular Imaging in Torino (26 to 28 May, 2013) Françoise Cailler, CEO of SurgiMab, will present the company’s R&D programs during the “Intra-Operative Imaging” session, Monday May 27th at 3:00 pm in a short oral presentation. A poster will also be presented Tuesday May 28th from 9:00 to 10:30 (Framery et al, Intraoperative near-infrared immuno photodetection of advanced ovarian tumors with the use of a novel specific conjugate targeting AMHRII. Poster n°177.)

Previous Post
In the press : “SurgiMab to sign a deal with a French CMO…”
Next Post
8th CHIP meeting in Montpellier

Recent Posts

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
  • SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.
  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
SurgiMab
Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
Home . Legal & credits
Copyright © 2023 SurgiMab. Website by B-to-B Design